At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,313 enrolled
Drug / intervention
Pradaxa (dabigatran) +1 moredrug
Likely dose
Pradaxa (dabigatran) 110mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation.
In Brief
An observational study evaluating Pradaxa (dabigatran) and Vitamin K antagonist for Atrial Fibrillation. Completed, enrolled 1,313 participants across 50 sites in 5 countries.
Detailed Summary
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesIndonesia, Malaysia, Singapore, South Korea, Thailand
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedJul 2016
Primary CompletionDec 2017
TodayJul 2026
First PostedJul 29, 2016
Enrollment StartJun 20, 2016
Primary CompletionDec 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.9 years ago
Interventions
Pradaxa (dabigatran)drug
Pradaxa (dabigatran etexilate)110mg or 150mg
Vitamin K antagonistdrug
Vitamin K antagonist or Pradaxa